PMGC Holdings Stock Price, News & Analysis

Elevai Labs Inc. (NASDAQ: ELAB) has announced a 1-for-200 reverse stock split effective November 27, 2024, to maintain Nasdaq listing compliance. The split aims to meet Nasdaq's minimum bid price requirement of $1.00 per share. After the split, approximately 3.07 million shares will be outstanding. Shareholders will receive one share for every 200 shares held, with fractional shares rounded up to one full share. While the trading symbol remains 'ELAB', a new CUSIP number (28622K 203) has been assigned. The split proportionally adjusts outstanding stock awards, options, and equity incentive plans without affecting overall shareholder equity value.

Elevai Labs (NASDAQ: ELAB) has withdrawn its previously announced exchange offer that would have allowed holders to exchange up to 15,000,000 shares of Common Stock for an equal number of newly issued Series B Preferred Stock. The withdrawal was due to the Depositary Trust Company's inability to accept Common Stock tenders due to logistical issues. The company had planned to complete this offer before a reverse stock split but faced delays from SEC comment responses. Elevai will now focus on regaining Nasdaq listing compliance and will evaluate the possibility of initiating a new exchange offer, though terms and execution are not guaranteed.

Elevai Labs (NASDAQ: ELAB) reported Q3 2024 financial results with mixed performance. Revenue decreased 4.9% to $527,478 for Q3 2024, while nine-month revenue increased 72.3% to $1.7M. The company achieved improved gross margins of 74.7% in Q3 2024, up from 66% in Q3 2023. Operating expenses increased to $1.3M in Q3, resulting in a net loss of $1.5M.

The company completed an $8 million public offering to support growth initiatives. Key developments include preclinical advancements in obesity treatment with EL-22 and EL-32, positive clinical results for Elevai Enfinity™, and expansion of their patent portfolio. Research partnerships with Yuva Biosciences and Dalhousie University strengthened their position in hair restoration and exosome technology.

Elevai Labs (NASDAQ: ELAB) has extended its Offer to Exchange program until November 27, 2024. The offer allows holders of Common Stock to exchange up to 15,000,000 shares for an equal number of newly issued Series B Preferred Stock. Key aspects include: the Series B Preferred Stock will be restricted and non-tradeable, potential pro-rata adjustments if oversubscribed, no capital appreciation rights, and possible dilution risks from future preferred stock issuances. The Board of Directors has not provided a recommendation regarding participation in the exchange offer.

Elevai Biosciences, a subsidiary of Elevai Labs Inc. (NASDAQ: ELAB), has engaged KCRN Research, Inc. to support its regulatory planning efforts for EL-22, a novel myostatin asset for potential obesity treatment. The company aims to submit an Investigational New Drug (IND) application to the FDA in 2025 and initiate clinical trials in the U.S. to evaluate EL-22 in combination with GLP-1 receptor agonists for obesity treatment.

EL-22 is an engineered probiotic targeting the myostatin pathway, which regulates muscle. It may offer a solution to muscle wasting, a common side effect of popular GLP-1 weight-loss medications. Preclinical results have shown improvements in dystrophic features of mdx mice. The company believes EL-22's oral approach differentiates it from other injectable myostatin strategies being tested for obesity treatment.

Elevai Biosciences, a subsidiary of Elevai Labs Inc. (NASDAQ: ELAB), has released encouraging preclinical data from 2022 for EL-32, a dual-action blocker targeting myostatin and activin-A. The study, conducted on aged C57BL/6J mice over 15 weeks, showed statistically significant improvements in grip strength, motor function, and body composition. Elevai believes EL-32 could potentially treat obesity when used alongside GLP-1 receptor agonists by preserving muscle mass while reducing fat mass.

Key findings include:

• Enhanced grip strength at week 15
• Improved motor performance with longer rotarod latency durations
• Optimized body composition demonstrated by DEXA scans

Elevai plans to conduct additional animal studies to advance EL-32 towards an Investigational New Drug (IND) application. Full preclinical data is expected to be presented at a future scientific conference.

Elevai Labs, Inc. (NASDAQ: ELAB), a leader in medical aesthetics, has announced an exchange offer for up to 15,000,000 shares of its common stock. Shareholders can exchange their common stock for newly issued Series B Preferred Stock on a one-for-one basis. The offer expires on November 5, 2024, at 5:00 P.M. New York City Time, unless extended or withdrawn.

Key points:

• Stockholders must tender all of their common stock to participate
• The exchange is subject to terms and conditions in the Offer to Exchange dated October 4, 2024
• Full details are available in the Offer Documents and Schedule TO filed with the SEC

Elevai Labs, Inc. (NASDAQ: ELAB) has announced the filing of two new patent applications for its lead candidate, EL-22, targeting muscle loss treatment in obese patients. These applications cover EL-22 as a monotherapy and in combination with GLP-1 receptor agonists. EL-22, an engineered probiotic expressing myostatin, aims to preserve muscle mass while reducing fat mass during obesity treatment.

The company has completed a Phase 1 clinical trial in South Korea, demonstrating EL-22's safety and tolerability. Elevai plans to assess its efficacy in combination with leading weight-loss therapies to address muscle wasting, a common side effect of GLP-1 medications. With these new filings, Elevai Biosciences' patent portfolio now includes 4 patent applications and 5 issued patents, providing protection in key markets such as the USA, Japan, China, and Korea.

Elevai Labs, Inc. (NASDAQ: ELAB) has announced the launch of a clinical study to evaluate the efficacy of its topical exosome products, Elevai empower™ and Elevai enfinity™, in combination with energy device treatments for facial skin rejuvenation. The study, conducted in collaboration with Dr. Jennifer Pearlman, aims to enroll up to 20 subjects aged 35-75 with various skin conditions.

The 12-week study will assess the products' efficacy as standalone treatments and in conjunction with energy devices, measuring tolerability, safety, and improvements in overall facial appearance. Elevai expects to announce topline data by Q1 2025 and publish results in a peer-reviewed journal.

This initiative aligns with the growing energy-based aesthetic device market, projected to reach $5.60 billion by 2030. Elevai is actively seeking partnerships with energy device companies to explore synergistic opportunities in the field of non-invasive skin rejuvenation.